What is the half-life of digitoxin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

In healthy volunteers with normal renal function, digoxin has a half-life of 1.5 to 2.0 days. The half- life in anuric patients is prolonged to 3. 5 to 5 days.

The half-life of digitoxin is not directly mentioned in the provided drug labels. The information provided is about digoxin, not digitoxin. Digitoxin and digoxin are two different drugs, although they are both cardiac glycosides. Therefore, no conclusion can be drawn about the half-life of digitoxin from the provided information. The FDA drug label does not answer the question.

From the Research

Half-Life of Digitoxin

The half-life of digitoxin is reported to be around 5 to 6 days in patients receiving usual doses, irrespective of renal function 1. This is consistent with another study that found the half-life of digitoxin to be approximately 5 days in patients with normal renal function 2.

Factors Affecting Half-Life

  • The half-life of digitoxin is not significantly affected by renal function, as it is mainly eliminated via the liver and metabolized in the body 1.
  • Hepatic cirrhosis does not seem to significantly affect the half-life of digitoxin, with studies showing similar half-lives in cirrhotic patients and normal subjects 2.
  • The half-life of digitoxin can vary between individuals, with one study reporting a mean half-life of 8 days in healthy volunteers 3.

Comparison with Digoxin

  • Digitoxin has a longer half-life compared to digoxin, which has a half-life of around 26 to 45 hours in healthy individuals 4.
  • The half-life of digoxin is more affected by renal function, with impaired kidney function leading to a prolonged half-life 1, 4.

Clinical Implications

  • The longer half-life of digitoxin may result in a lower incidence of toxic side effects compared to digoxin, due to a more stable pharmacokinetic profile 5.
  • The slow accumulation of digitoxin may require a loading dose to achieve therapeutic levels quickly, with a suggested loading dose of 12 times the maintenance dose 3.

References

Research

Pharmacokinetics, bioavailability and serum levels of cardiac glycosides.

Journal of the American College of Cardiology, 1985

Research

Digitoxin accumulation.

British journal of clinical pharmacology, 1982

Research

Clinical pharmacokinetics of digoxin.

Clinical pharmacokinetics, 1977

Research

Treatment of congestive heart failure--current status of use of digitoxin.

European journal of clinical investigation, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.